Source: PR Newswire

Press Release: Sierra Oncology : Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO

- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1st - - Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3rd featuring distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit -...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Stephen Dilly's photo - President & CEO of Sierra Oncology, Inc.

President & CEO

Stephen Dilly

CEO Approval Rating

90/100

Sierra is a clinical-stage drug development company that researches, develops and commercializes therapeutics for the treatment of cancer. Read more